1. Long-Term Follow-Up of Percutaneous Coronary Intervention With Paclitaxel-Eluting Balloon Catheter.
- Author
-
Sanchez-Perez, Ignacio, Abellan-Huerta, Jose, Jurado-Roman, Alfonso, Lopez-Lluva, Maria T., Pinilla-Echeverri, Natalia, Perez-Diaz, Pedro, Piqueras-Flores, Jesus, and Lozano-Ruiz-Poveda, Fernando
- Subjects
- *
CORONARY artery injuries , *CARDIAC surgery , *CEREBRAL small vessel diseases , *PERCUTANEOUS coronary intervention , *DRUG-eluting stents , *HEALTH outcome assessment , *SURGERY , *PATIENTS , *CORONARY restenosis , *DESCRIPTIVE statistics , *CATHETERIZATION , *PACLITAXEL , *LONGITUDINAL method ,PREVENTION of surgical complications - Abstract
Drug-eluting balloons currently constitute a therapeutic tool used in percutaneous coronary interventions (PCI). Long-term results remain unknown. We evaluated the prognosis of PCI using a second generation paclitaxel-eluting balloon (PEB) in real-world patients. We included all PCI with PEB in de novo or in-stent restenosis coronary lesions performed in our unit from March 2009 to March 2019. We assessed the composite of major adverse cardiovascular events (MACE) rate after a median follow-up of 42 months. Consecutive patients (n = 320) with 386 lesions were included; 46.9% presented with stable angina and 53.1% acute coronary syndromes; 52.6% of the lesions were in-stent restenosis and 47.3% de novo lesions with a mean diameter of 2.4 ± 0.5 mm. A bare metal stent was implanted in 6.7% and a drug-eluting stent in 8.5% of patients. The MACE rate was 8%: 10 (2.6%) cardiovascular deaths, 13 (3.4%) myocardial infarctions, and 16 (4.1%) target lesion revascularization. The all-cause death rate was 5.2%. No cases of thrombosis were recorded. In conclusion, PEB was a safe and effective tool to treat in-stent restenosis and de novo coronary lesions, especially small vessel disease, during long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF